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FOREWORD 
A realistic evaluation of progress under the EEC Human Genome analysis programme 
must take into account how similar projects have developed elsewhere, so as to highlight in 
a comparative way strengths and weaknesses of the European enterprise. First-hand knowledge 
of actual progress in other countries is here essential, since the quality and efficiency of 
research cannot be accurately assessed from documents alone, especially in such a rapidly 
developing and evolving field. I provide here such an assessment, based on direct contacts and 
on-site visits to a number of genome centres world-wide. The groundwork for this was laid 
by a one-year study I performed in 1991, during which I visited in depth approximately 100 
major genome laboratories all over the world. This has been updated through further visits and 
discussions with a number of scientists in these countries, and the resulting document is a 
personal, probably biased but at least candid account based on both facts and impressions. 
Only references to recent publications (1993, 1992, and in a few cases 1991) are given. 
Bertrand R. Jordan, March 1993 
IX 
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I. INTRODUCTION 
Serious discussion about launching a human genome sequencing programme began in 
the USA in the mid-eighties. By 1986-87, the Department of Energy had committed several 
tens of millions of dollars to this effort, shortly followed by NIH. Over succeeding years 
funding grew to a total of close to 200 million dollars per year, while goals were redefmed 
to focus on genetic and physical mapping with a smaller component devoted to DNA 
sequencing. Other countries followed suit, notably Japan (with, however, four or five different 
programs whose coordination took time to become effective) and Great Britain with a well-
integrated Human Genome Mapping Project. The Soviet Union started a project in 1989, 
although efforts were hampered by lack of hard currency, communication problems and by 
the subsequent disintegration of the Union; France has also been present in the field with both 
an official genome programme and a very successful project run by non-governmental 
organizations (CEPH, AFM and Généthon). Each of these non-US national projects has its 
distinctive flavour, and most appear more strongly focused on functional genes than the US 
enterprise - although the latter turned out to be the first to set up on a large scale the very 
effective partial cDNA sequencing approach. Relative strengths of these countries in the field, 
in 1990-1991, can be summarized as shown in Figure 1; the different indicators used give 
roughly equivalent results, with the USA a clear leader, Great Britain a strong second and 
France a more distant third, slightly ahead of Japan; on a continental basis the EEC (Britain 
included) is almost equivalent to the US. Recent successes in Europe (sequencing yeast 
chromosome UJ) and notably in France (the Généthon genetic and physical mapping 
programmes) are increasing the share of Europe in this field. Figure 2 indicates approximate 
funding levels in 1993 for some of these national projects. 
In spite of the short time since Genome programmes were initiated, it is abundantly 
clear that they have numerous consequences. They push recombinant DNA technology towards 
more powerful and efficient procedures, which can benefit many other fields of research; they 
have important potential commercial implications (in terms of diagnosis and therapy), as 
evidenced by the - now almost settled? - controversy on patenting of partial cDNA sequences; 
and they raise socioeconomic as well as ethical problems that are not easy to address. 
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Π. REVIEW OF MAJOR NATIONAL PROGRAMMES 
Π A. UNTIED STATES 
Π A 1. Current plan and major participants 
The US genome programme has suffered a period of uncertainty following the 
resignation of Jim Watson, head of the NIH component, over disagreements with the director 
of NIH on, in particular, patenting of cDNA sequences. An interim director (Michael 
Gottesman) had been appointed, but clearly future directions will depend very much on 
Watson's successor, Francis Collins, whose appointment has recently been announced 
(Thompson, 1993). The present five year plan is now beginning its third year. Its major goals 
are: completion of a 2 to 5 centimorgan genetic map in which each marker is identified by an 
STS; construction of STS­based physical maps with 100 kilobase average spacing and progress 
towards genome coverage with large (>2 megabase) contigs; ünprovement of DNA sequencing 
methods and determination of approximately 10 megabases of sequence in large stretches; 
derivation of a detailed genetic map of the mouse as well as sequence data and physical maps; 
and, finally, development of software, databases and algorithms. 
Some of these goals now appear too modest in the face of recent developments, a point 
we will discuss in the general conclusion. 
Π A 2. Assessment of progress 
A caveat 
The following comments, as well as those I will provide for other countries, are both 
qualitative and personal. While based on site visits to the centres quoted and on extended 
discussions, they are also highly subjective and their conclusions are certainly debatable. I feel 
however that they represent the most valuable contribution I can make since they give a first­
hand feeling about ongoing research as experienced by a scientist in the same field. They 
should usefully complement objective data on results and pubücations. Any value judgments 
made are entirely my responsibility. 
The DOE juggernaut. 
DOE runs three major genome centres, at Lawrence Livermore, Los Alamos and 
Lawrence Berkeley. The latter has been without a director for a long time, following Charlie 
Cantor's "sideways promotion" at fall 1990; the acting director, Jasper Rine, has now been 
confirmed, but many scientists left or drifted apart during the long interim period, and I do 
not feel the centre has really resumed effective operations ­ especially since its major topic, 
chromosome 21, has been effectively taken up by others, in particular Daniel Cohen's group 
at CEPH and Généthon (Chumakov et al, 1992 b). 
The other centres, Los Alamos and Lawrence Livermore, both have responsibility for 
providing chrcmosorne­specific libraries, which they have done on the whole/with success, 
moving progressively from small insert to large insert lambda libraries and now to cosmids; 
these libraries have been tremendously useful to the whole community. Efforts at Los Alamos 
to extend this approach to YAC libraries derived from flow­sorted chromosomes appeared 
promising but are superseded by the more efficient method of "extracting" chromosome­
specific collections from whole genome YAC libraries (Chumakov et aL 1992 a; Ross et aL 
1992). The two centres have also undertaken the construction of whole chromosome physical 
maps (respectively chromosomes 16 and 19) through cosmid contigs assembled by two 
variants of a fingerprinting method. This heroic effort, started just when YACs were appearing, 
has achieved relatively good but still incomplete coverage (Stallings et al, 1992; Trask et al, 
1992): at this time the cosmid contigs span only slightly more than half of chromosome 16 
and 19. The physical map is now being completed with the help of YACs; there is much to 
be said, in fact, for a physical map based on both YACs and cosmids, since the latter are 
usually the most useful for any group interested in a particular region. Both centres 
are run in a professional way, with good organization and stable personnel; this is particularly 
the case at Lawrence Livermore. Both suffer from lack of sufficient flexibility, limited contact 
with other laboratories (few post-docs and no students) and from the fact that serious physical 
mapping may have been started too early so that major technical options were frozen based 
on technology which quickly became obsolete. 
Wholly YAC-based physical efforts have now proved very effective (Chumakov et aL 
1992 b; Bellanne-Chantelot et aL 1992; Foote et aL 1992; Green et aL 1991 a) and 
réévaluation of the DOE programmes becomes necessary. DOE contractor's meetings, attended 
by all groups receiving DOE funding, gave me a cross section of this effort which is of good 
quality and has a strong technological orientation. On the whole my impression of DOE (apart 
from the Lawrence Berkeley centre, beset by serious political problems) is that of a technically 
competent operation, with reasonable goals and qualified personnel, but lacking some of the 
flexibility and brilliance necessary in such a rapidly evolving field. 
The NIH kaleidoscope 
NIH is much more difficult to characterize because of its great diversity. Genome 
centres funded by this agency range from heavyweight physical mapping groups operating 
almost exclusively with technicians (e.g. Glen Evans, Salk Institute, for chromosome 11) or 
with a more traditional mix of post- docs, students and technicians (e.g. David Schlessinger 
and Maynard Olson, Washington University of Saint-Louis, for chromosomes 7 and X) to 
departments mostly involved in disease-oriented research (Tom Caskey, Baylor Institute at 
Houston, with a partial focus on chromosomes 17 and X). 
In the latter case the genome grant is used to set up very effective "core services" (for 
YAC screening, sequencing, informatics...) used by the research groups in the departments as 
well - in principle - as by outside users. In contrast, the operation at Saint-Louis is completely 
devoted to developing a complete physical map of the two chromosomes in question, using 
a very robust STS-based contig building approach. This programme is pursued with great 
dedication and a commitment to avoid sidestepping into lateral projects - even though 
appealing opportunities may arise. Needless to say, there is a fair amount of tension between 
groups which are funded by the same programme but pursue such widely differing objectives. 
On the whole work carried out in the NIH framework appears more trendy, more open 
to new concepts and more innovative than the research performed under DOE. On the other 
hand, it seems often less well organized; it benefits from the presence of good students and 
post-docs but suffers from the instabihty of this personnel which lacks dedication to long-term, 
systematical objectives and tends to rush into "exciting" sidelines. 
Π A 3. General commente (scientific) 
Geneticmaps 
The human genetic map appears to be progressing well, after a period of 
disillusionment and scepticism in 1989-1990. The shift from RFLPs to CA or other simple 
sequence repeats is general, although a number of technical problems remain: on one hand, 
the tendency of these repeats to yield multiple bands complicates scoring of the results, and 
difficulties persist in streamlining the procedure and developing automatic data capture. Sperm 
mapping does not appear to have caught on as an effective fine-scale mapping method, 
although new developments appear very promising (Zhang et al, 1992). The scientists involved 
appear confident that a map with an average marker density of one marker per two 
centimorgans (not all ordered) can be produced by the end of the current 5 year plan (1995). 
A "MH/CEPH" comprehensive linkage map including 1416 loci has been obtained by 
a constellation of collaborating laboratories using the CEPH panel of families (NIH/CEPH 
collaborative mapping group, 1992). In spite of the magnitude of this achievement, the 
usefulness of this map is limited by the fact that most loci correspond to moderately 
informative markers, RFLPs rather than microsatellites. In addition, it appears likely that 
genetic distances are somewhat overevaluated because the data (collected by many groups of 
non-uniform expertise) includes some typing errors - that tend to increase the apparent 
recombination rate and thus the map distances. In both these respects the genetic map recently 
obtained at Généthon by Jean Weissenbach's group (Weissenbach et al, 1992) appears superior 
as it is solely based on microsatellites and relies on data of uniform (and high) quality. 
Physical nwps 
The advancement of physical mapping appears more uneven. As indicated above, the 
early start of DOE cosmid contig efforts means that much work has been done using a 
technology that is now largely obsolete; on the other hand these contigs, with the addition of 
selective YAC coverage, were the first to show that a physical map of a whole human 
chromosome was feasible. More recent attempts such as those implemented in Saint-Louis 
have every chance of success if they are pursued to the end; but these approaches are 
superseded by the much more efficient YAC fmgeiprinting techniques used, in particular, at 
Généthon in France (Bellane-Chantelot et aL 1992). The successful mapping project on the 
Y chromosome (Foote et aL 1992) has been set up for the most part outside the "official" 
genome projects. The whole programme will obviously have to be reevaluated. 
Cytogenetics 
Cytogenetics, once thought to be almost a dying art, has enjoyed an astonishing revival 
thanks to the development of very effective non-radioactive in situ hybridization techniques. 
Metaphase in situ has become a highly efficient and quick way of mapping cosmids and YACs 
to a precision of one chromosome band; interphase in situ with multicolour technology can 
provide ordering of clones separated by a hundred kilobases or even less. In addition these 
developments have direct application in clinical genetics, using chromosome painting or two-
colour interphase in situ for the detection of translocations. The two world leaders in the field 
are probably David Ward (Yale) and Barbara Trask (Lawrence Livermore), but the technology 
has now spread to a large number of laboratories all over the USA and is extremely effective. 
(31 
Sequencing 
Large scale sequencing of genomic DNA is not a major objective of the present DOE 
and NIH programmes - not unless cost can be brought down to much less than one US dollar 
a base: the current 5 year plan envisions a total of 10 megabases of human DNA and twice 
as much for model organisms. Recently completed genomic segments include a 106 kilobase 
segment from chromosome 19 (Martin-Gallardo et al, 1992), a 95 kilobase region containing 
part of the mouse Τ cell receptor alpha/delta locus at Caltech (Wilson et aL 1992) and the 
Nematode sequencing work carried out in Saint-Louis in collaborating with the British group 
(Sulston et aL 1992). 
New technologies are still under investigation, although enthusiasm for direct sequence 
reading by STM or AFM microscopy has very much died down. The single-molecule detection 
system proposed by R. Keller (Los Alamos) is nearing the feasibility demonstration stage (and 
is being developed in collaboration with Gibco-BRL) but practical applications are probably 
still far in the future. More evolutionary developments such as ultrathin gels, capillary 
electrophoresis or the use of new enzymes and reporter groups may significantly improve the 
performance of present technology. DNA sequencing by hybridization, as originally proposed 
by soviet (Pevzner et aL 1991) and Yugoslav scientists, is now considered a serious possibility 
(Cantor et al, 1992 a); it is mainly explored, in me USA, by GenjakoVs group at Argonne 
(DOE). 
cDNA sequencing has been taken up very effectively by Craig Venter's group (although 
not with genome funding) and others (Adams et al, 1991; Adams et al, 1992; Khan et aL 
1992), and attempts at patenting the partial cDNA sequences have caused a well-known 
national and international controversy. This approach may become a major focus of the US 
genome effort; Jim Watson was opposed to this choice, but his successor may well hold a 
different opinion. 
Π A 4. General commente (organizational) 
DOEvsMH 
As indicated above, the two agencies have definitely different styles. They are to a 
certain extent complementary, but my impression is that this complementarity is not 
sufficiently exploited. There iş interagency coordination at the higher levels, but day-to-day, 
lab-to-lab contact between DOE and NIH centres is not very intensive, in part because the 
major DOE centres are in outlying locations to which, in addition, access is sometimes 
restricted for security reasons. Thus contacts between groups are not sufficient, and some 
potential synergisms are not put into effect. -Ţ 
Manpower 
Genome centres find themselves with the dilemma of requiring some very qualified 
scientists, if only for definition of exrjerimental strategy and for trouble-shooting procedures, 
and yet assigning to them a majority of systematic and rather uninspiring tasks. Various 
centres try to tackle this contradiction in different ways, but the balance appears difficult to 
find. The status of many technicians in the USA, i.e. the fact that they are often former 
students who after a couple of years as technician will resume their studies and work for a 
PhD is helpful here, since it provides a flow of young technicians - in contrast with the usual 
situation in Europe where being a technician is a lifelong occupation. 
Informatics and instrumentation 
Although these two fields receive much attention and sizeable funding they continue 
to be rather badly integrated with actual everyday laboratory work. There are exceptions, in 
particular in DOE centres, but generally the gap between biologists and computer people is 
not completely bridged Instrumentation is another weak point, in spite of much-publicized 
efforts: nowhere, for example, is a colony-picking robot actually in everyday laboratory use, 
and robotics in Genome centres rarely go beyond one or two pipeting robots, usually Beckman 
Biomek or TECAM machines. Some DOE centres (notably Lawrence Livermore) have had 
more success in breaking down cultural barriers between biologists, software experts and 
robotics engineers, possibly because the stable employment structure of genome centers in this 
agency makes possible long-term contact between specialists from different fields. 
Π A 5. Recent developments 
The most important recent result from the US is probably the physical map of the Y 
chromosome recently published by David Page's group (Foote et al, 1992), as well as rapid 
progress on the mouse genome in Eric Lander's group. The other chromosome-specific 
mapping projects will have to be reevaluated; in fact a shift to whole-genome mapping has 
already taken place with the announcement of a large centre in Cambridge, Massachusetts, 
headed by Eric Lander and concentrating on large-scale STS content physical mapping - in 
collaboration with Daniel Cohen's group and using their "MegaYacs". This is funded at the 
level of 24 rrdlHon US dollars for five years. Another large centre in Iowa (15 million dollars 
for four years) will concentrate on generation of large numbers of microsatellite markers and 
genetic mapping (Anderson, 1992 b; Roberts, 1992). Thus the US programme - at least its 
MH component - is moving away from its previous single-chromosome approach. Meanwhile 
Craig Venter has resigned his MH post in July to head up a new "Institute for Genomic 
Research" (Anderson, 1992 a), funded by a corporate partner, Human Genome Sciences, Inc. 
This new institute has ordered 50 DNA sequencers and will go for cDNA sequencing on a 
very large scale. The company will retain commercial rights to discoveries made in the 
Institute (which it funds to the tune of 70 million dollars), but results will be published in the 
normal way. Corporate interest in human genome research and its applications has grown 
substantially during the last year and a number of ventures are underway (Figure 3 and 
Anderson, 1993 a). 
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Phoenix Partners 
Frederic Bourfce 
Human Genome 
Sciences Inc. 
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F I G U R E 3 
A l i s t , compiled by Science (Anderson 1993 a) of 
commercial ventures in the US involving human genome research . 
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Π RIOPAN 
Π Β 1. Ornent plan and major participants 
There are several genome programmes in Japan, corresponding to the different agencies 
involved and funded for a total of approximately 20 million US dollars in 1992. The project 
of the Ministry of Education (Monbusho), headed by Kenichi Matsubara, a very well­respected 
scientist, is centred on fundamental research including cDNAs, general genetic and physical 
mapping (without focus on a particular chromosome), informatics, technical developments and 
sequencing of DNA from model organisms (Schizosaccharomyces pombe, Bacillus subtihs...). 
1992 funding for Monbusho was around 6 million US dollars. The Science and Technology 
Agency (STA) has a more technological programme focussed on chromosomes 3, 11 and 21, 
funded at the level of 8 million; the ministry of Health has a smaller project (3 million) on 
genetic diseases. In addition the Ministry of Agriculture funds research on the rice genome (3 
million) and the Ministry for International Trade and Industry (ΜΓΠ) in involved in setting 
up sequencing institutes with industries and local governments. A committee headed by 
senator Mori has been set up since 1991 to coordinate these various efforts. 
Π Β 2. Assessment of progress 
STA îs renûmscent of DOE 
There are more than superficial analogies between the two agencies, since STA, like 
DOE, is a government agency primarily involved in energy research and general technological 
development. Its biology has therefore a fairly instrumental and systematic aspect ­ as is the 
case for DOE. Two main STA centres are involved in genome work the RIKEN life sciences 
centre in Tsukuba, and a division within the National Institute of Radiological Sciences in 
Chiba (both close to Tokyo). RIKEN houses the "HUGA sequencing factory" (Endo et al, 
1991) which is the outcome of Akiyoshi Wada's efforts, started more than ten years ago. This 
is a complete set of robots perfcarning each step of (conventional) sequencing, linked into a 
system in which transport of samples from one machine to the next is taken care of more or 
less automatically. A very impressive and unique set up demonstrating the technological 
expertise of the Japanese and their capacity for long­term investment. Actual results from use 
of this set­up are awaited with interest: the theoretical throughput is more than 100,000 bases 
of raw sequence per 24 hours. Not surprisingly, teefhing troubles have hit HUGA, and it is 
not yet in actual production; it nevertheless represents a very interesting and unique effort. 
The Chiba group is a more conventional cytogenetics laboratory which localizes 
cosmids by non isotopie in situ hybridization with good results and efficiency, as shown by 
the recent localization of nearly three hundred chromosome 3 cosmids (Takahashi et aL 1992). 
It is closely associated with the group of Yusuke Nakamura (formerly at Salt Lake City) who 
studies chromosomes 3 and 11 in the context of a private cancer institute, but with heavy 
funding from STA This is a very impressive group which has recently scored some 
spectacular hits and is a very serious competitor for the best groups in the West. Overall STA 
appears well funded, highly technological and well­connected with industry, but sometimes 
not close enough to biologists ­ although this has changed, and STA grants are now being 
obtained even by university groups, a feat previously unheard of. 
11 
Monbusho is more academic 
There are a number of excellent molecular biology groups in Japan, such as Honjo 
(Immunoglobulins), Okayama (cDNAs and the cell cycle), Yanagida (S. pombe) as well as 
Matsubara and others. The Monbusho programme attempts to bring together the expertise from 
these groups in a genome context but without setting too stringent criteria on the topic. 
Awareness and expertise in up to date technology has undoubtedly increased, for example in 
pulse field gel work and use of YACs, and the "soft" coordination promoted by Matsubara 
appears to be effective. Of particular interest is the tack taken by Japanese groups with regard 
to cDNA studies: they have opted for tiie construction of cDNA libraries reflecting as closely 
as possible the mRNA content of the corresponding tissue, i.e. the opposite direction to those 
who invest in "normalization" procedures. The plan is to sequence 1000 cDNA clones for each 
of the 200 basic cell types, and thus to obtain a sample of the genes expressed in these tissues 
as well as of their level of transcription (Qkubo et al, 1992). 
Π Β 3. General comments (scientific) 
A late but effective start 
Compared with the state of affairs three or four years ago, Japanese involvement in 
human genome research has undoubtedly taken off. This is quite visible in international 
meetings, where presentations from Japanese scientists in this field tended to be somewhat 
second rate, and are now often of excellent scientific and technical quality. Some of the work 
done in university laboratories is superb (e.g. Matsuda's coverage of the Ig region by YACs, 
in Honjo's group), while the level of STA research has definitely improved 
Emphasis on sequencing 
There does not appear to be any systematic genetic mapping (except for the 
collaborative work involving Nakamura), and it is doubtful whether physical mapping of 
whole chromosomes will be seriously attempted (chromosome 21 was announced, but this in 
now essentially obsolete). On the other hand, sequencing seems to receive a lot of attention. 
cDNA sequencing projects (using the "signature" approach) are underway in several groups 
including Matsubara's; as indicated previously, the Japanese approach stresses the use of this 
method as a way to assess the expression patterns in different tissues. In addition, large-scale 
genomic sequencing (not necessarily of human DNA) is being prepared for not only by STA 
at RIKEN but in one or two other special-purpose institutes funded by industry, local 
governments and ΜΓΠ. This may become quite a strong Japanese contribution to the genome 
project. 
Π B 4. General comments (oigaazational) 
A special context 
There are several reasons for Japan's modest position in genome research in the recent 
past. For cultural reasons (inherited diseases are looked upon as shameful) clinical genetics 
has remained underdeveloped, and has not served (as in other countries) as foundation and 
spur for genome research. In addition, strong disagreements between competing agencies have 
reduced the efficiency of research and delayed the initiation of proper genome programmes. 
However these difficulties appear to be largely overcome, and Japan has definitely got its act 
together, thanks in part to the influence of Kenichi Matsubara The Japanese capacity for long-
term investment (as for the HUGA sequencing factory) is also beginning to pay off. 
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Progress in instrumentation is particularly striking, and the Japanese industry may well market 
in the near future instruments such as budget-priced "personal sequencers" which could be a 
great hit. 
Π Β 5. Recent developments 
The 1993 budget includes healthy increases for genome research: total funding is 
around 3,000 million yen (i. e., close to 30 million US dollars) with 7.5 million (US dollars) 
to Monbusho, 10 to STA, 7.5 to the Ministry of Agriculture and Fisheries (rice genome) and 
5 to the Ministry of Health. 
Informatics and databases are still the subject of some discussions between Monbusho 
and STA, but a Genome centre largely dealing with informatics (directed by Kanehisa and 
funded by Monbusho) is being set up at the Institute of Medical Science (Tokyo University). 
STA has responsibility and should eventually - when some bureaucratic hurdles are cleared -
get funds for organizing the Japanese GDB node. Reliable accounts indicate, on the other 
hand, that the HUGA sequencing factory has not reached actual operation and may never do 
so... 
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I I C GREAT BRITAIN 
I I C 1 . Current plan and major participants 
After extensive discussions between the two major players in this field, namely the 
Medical Research Council and Imperial Cancer Research Fund, the Human Genome Mapping 
Project was officially initiated in 1989, with separate funding of 11 million pounds for three 
years, thereafter to be continued at the level of 4 million per year (but at that later stage 
incorporated into the MRC funding baseline, in open competition with other fields). Major 
goals were genetic mapping, localized physical mapping, cDNA studies and model organism 
sequencing, notably the Nematode. In addition a Resource Centre was set up to provide 
logistic help to groups (probes, oligonucleotides, YAC library screening, computer services...). 
The various aspects of the HGMP have been implemented, and information is provided by an 
regular newsletter, "G-nome news". 
Π C 2. Assessment of progress 
The "Resource Centre"is indeed service-oriented 
The HGMP resource centre, located in the western suburbs of London, has developed 
into a facility providing a range of services to many laboratories. YAC screening, probe and 
primer provision are particularly popular, as well as the computer services which provide 
access to the major genome databases (GDB, OMIM, GBASE...) as well as to a variety of 
software. The cDNA sequencing activity is more self-centred at this stage, but will provide 
information and reagents to the outside world (the confusion arising from the reaction of MRC 
to cDNA patents is now cleared up), and the mouse backcross should prove extremely useful 
to groups wishing to map quickly a few sequences on the mouse genome. To my knowledge 
this is one of the few cases in which a facility set up and advertised as a service lab actually 
functions almost entirely as such! 
Highly 'genomic"'laboratories 
The number of groups involved in systematic, large-scale studies is not large. Two of 
them are particularly noteworthy: Hans Lehrach's "genome analysis laboratory" at ICRF, and 
Alan Coulson and John Sulston's group at LMB, Cambridge. The ICRF group has proposed, 
developed and implemented a number of highly original and efficient technical approaches to 
map large genomes, notably the extensive use of high-density gridded filters, contig building 
by oligonucleotide hybridization and the "reference library" concept (Nizetic et aL 1991). 
These have resulted in significant achievements such as the assembly of cosmid contigs over 
the S. pombe genome (Maier et aL 1992), but the whole potential of these highly intelligent 
technologies has not been realized so far, possibly because the number of topics and organisms 
studied is too large. To a certain extent, Hans Lehrach's objective was to achieve one of the 
major goals of the genome programme (physical mapping of the whole genome) ahead of the 
US project, thanks to a more intelligent and well-organized strategy. At this time (early 1993), 
it appears that this effort has not really succeeded, while Daniel Cohen's groups, at CEPH and 
Généthon, is on the way to achieving this with somewhat less astute but more seriously 
implemented methods. 
The LMB team has completed the physical map of the Nematode and successfully 
initiated large-scale sequencing, using a very rational and flexible approach which involves 
both ABI and Pharmacia sequencers at different stages of the process (Sulston et aL 1992). 
15 
(4) 
Integration of clinical genetics and genome research 
Many groups, laboratories and research units in Great Britain combine some genomic 
work with focussed clinical genetics, using very up to date technology. Examples abound: 
several groups at ICRF, in Oxford (e.g. Tony Monaco, Kay Davies and others), and institutes 
like the MRC Human Genetics Unit in Edinburgh show a high degree of quality and 
integration. These groups appear to use the HGMP framework and services quite effectively 
to advance their goals. 
Π C 3. General eoamente (scientific) 
Different degrees of emphasis 
Genetic mapping does not seem to be particularly emphasized in Great Britain, 
although it is very competently done in the context of focussed (disease-oriented) projects. 
Physical mapping is more a strong point, rooted both in the tradition of cosmid fingeiprinting 
pioneered by Alan Coulson and John Sulston and pursued by others, and in the elegant 
methods set up by Hans Lehrach. Sequencing is definitely a major aspect in this country, both 
with elaborate manual methods (Bart Barrell) and with an efficient combination of different 
machines, as indicated above, for the Nematode project 
Originality and inventiveness 
A number of original methods or approaches are developed Ed Southern's "tethered 
oligonucleotides" system (Southern et al, 1992) which should have a major impact on 
diagnostics and maybe on sequencing, clever manipulation of chromosomes to obtain ordered 
sets of progressively shortened chromosomes in Howard Cooke and Peter GoodfelloWs groups 
etc... 
Π C 4. General conmente (orgaizational) 
Good information flow and coordination 
Communications within the genome community and with clinical geneticists appear 
quite good; the HGMP newsletter (G-nome News) provides an effective link, contains a high 
proportion of practical information and does not avoid discussion of delicate issues (viz Tony 
Vicker's features about instrument manufacturers or the MRC stand on cDNA patenting). This 
is in contrast with the US newsletter which is much more formal and usually avoids 
controversial topics (such as Cantor's removal, Watson's resignation or, in the last issue, 
success on the chromosome 21 map in France). Many other channels of communication and 
in particular a multitude of small meetings also improve information flow. 
Good value for money 
In general genome research in Britain appears highly inventive, possibly in reaction to 
a general lack of funds; this leads to a good ratio of results to funding. Operations like the 
LMB nematode group are particularly impressive in this respect. On the other hand financial 
limitations may sometimes imperil highly innovative but money-intensive approaches like 
Hans Lehrach's - which would probably have flourished much better in an environment like 
"Généthon" (see the section about France). Finally the excellence of clinical genetics in Britain 
provides good research opportunities and speedy application of new results. This positive 
picture may not last if funding problems persist, as even now this really hampers a number 
of very good projects; 
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Π C 5. Recent developments 
The most noteworthy is the definite plans for setting up the "Sanger Institute", funded 
by the Wellcome trust and probably located in Cambridge, which will be devoted to megabase 
sequencing of the nematode under John Sulston as well as to other large scale sequencing 
projects. 
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HD. FRANCE 
U D I . Ornent plan and major participants 
The French situation with respect to genome research is complex and requires specific 
discussion. Although this is a rather delicate matter, I will try to provide a candid assessment 
Academic groups vs CEPH 
There are a number of good groups operating within INSERM and CNRS, the two 
major French research agencies. These enjoy stable funding and generally reasonable working 
conditions, but have very little flexibility in terms of large budget increases for specific 
projects or hiring of personnel (since it is largely a civil servant system, and hiring a person -
except a foreign post-doc - on grant money is almost impossible). Consequently these groups 
have generally remained close to medical genetics and have not been able to launch large-
scale (and expensive) genomic programmes. On the other hand CEPH, which is a private 
foundation ("association loi de 1901") but draws about half of its funding from the State, has 
much more leeway in terms of budget, personnel and generally methods of operation. CEPH 
has built on its success as coordinator of genetic mapping through the provision of DNA from 
a large panel of well-characterised families, and has ventured successfully into structural 
genomic studies. In particular the large-insert YAC library constructed at CEPH appears to be 
the best available at this time. 
AFM vs the 'public sector" 
The "Association Française contre les Myopathies", headed by a very dynamic 
president (Bernard Barataud) has become a major player in the genome field It has collected 
between 250 and 300 million French francs (30 to 40 MEcus) at each of its yearly telethons, 
and has invested a large fraction of these funds in research on genetic diseases. Part of these 
funds have been distributed through several grant programmes, but a major share has been 
used to set up and run, jointly with CEPH, the "Généthon" laboratory, which is partly a 
service lab but mostly a research institute. This is where most of the heavyweight genomic 
work is done in France. 
The genome programme of the Ministry of Research 
A French Genome programme was announced in October 1990, with 50 million 
(French Francs) new funding for 1991 and 100 million for 1992. Priorities stressed were 
cDNA studies, model organisms, informatics and some physical mapping. The actual 
implementation of this programme has been fraught with difficulties. Some granting decisions 
were made late in 1991, but these grants were honored only by late spring or summer 1992; 
a new scientific committee, headed by Piotr Slonimski, published a call for proposals in May 
1992 and allocated approximately 100 million to close to a hundred projects (some of them 
within CEPH or Généthon). Most of these grants have been finally approved and a further 80-
odd million francs are slated for 1993. 
A complex situation 
As could be expected, there are considerable tensions between these various 
foundations and agencies which have very contrasting motivations and also quite different time 
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constants. The slow start of the "official" genome programme is particularly unfortunate in this 
respect, since it could have been used to federate the different components involved in this 
work 
Π D 2. Assessment of progress 
Good quality academic groups 
Good research groups operate in INSERM or CNRS laboratories, such as Jean­Loup 
Mandel in Strasbourg (Fragile X, adenolencodystrophy), Judith Melki and Arnold Munnich 
in Paris (SMA) and a number of others. Recent successes in mapping or cloning a disease 
gene within these groups often involved help from ŒPH and/or Généthon: use of the 
extensive Southern blotting facilities at Généthon, of the CEPH YAC library, of Généthon 
blood and cell line banks... 
CEPH and Génähon 
CEPH has built on the "semi­industrial" expertise acquired while administering the 
genetic mapping panel to venture into heavyweight genomic work. Some endeavours (such as 
sequencing the MHC region) were unsuccessful (as other similar sequencing programs at the 
time), others such as the YAC library ended up, after initial difficulties, with excellent results. 
CEPH also became involved with ICRF and two firms, Amersham and Bertin, in the Eureka 
"Labimap" programme to develop a line of instruments for molecular biology. CEPH and 
Bertin are now the main, if not the sole, partners in this venture mat has had a complex and 
conflictual history, the first instrument, a Southern blotting machine, has been introduced on 
the market in October 1992. In addition, CEPH continues to be very much involved in genetic 
mapping, both as coordinator, e.g. for the "MH/CEPH map" (NIH/CEPH, 1992) and for in­
house work (Mark Lathrop's group). 
GénéÜion is a large facility (130 employees, mostly technicians, and a total yearly 
budget of 74 million French Francs) located just south of Paris. It has both service and 
research components, with large cell banking facilities and a set of twenty blotting machines 
on one hand, and several research groups on the other. Major ongoing pojects include YAC 
contig building over the whole human genome (Daniel Cohen), generation and assignment of 
a very large number of microsatellite markers (Jean Weissenbach), signature cDNA sequencing 
(Charles Auffiay) and others. Each of these projects involves sornething like twenty 
technicians and engineers, 15 million francs per year and heavy equipment. It is now clear that 
some of these endeavors are highly successful. The most visible is the physical mapping 
enterprise directed by Daniel Cohen which in 1992 demonstrated efficient selection of 
chromosome­specific YAC from a whole genome library (Chumakov et al, 1992 a), provided 
a continuous YAC contig map of chromosome 21 (Chumakov et al, 1992 b) and is on the way 
to a general YAC contig map of the whole human genome (Bellanne­Chantelot et al, 1992). 
The microsatellite generation and genetic mapping effort led by Jean Weissenbach is also 
highly productive, with more than a thousand markers already generated and organized in an 
effective "second­generation" genetic map (Weissenbach et al, 1992), while the cDNA project 
has already placed more man two thousand new partial sequences in public databases. 
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ΠΙ D 3. General comments (scientific) 
Genetic mapping 
The unique position of CEPH (sole provider world-wide of an extensive panel of 
individuals as DNA) provides a strong focus for genetic mapping in France. This is likely to 
be reinforced by the influx of highly polymorphic CA repeat markers originating from Jean 
Weissenbach's work at Généthoa Genetic mapping is also performed by several groups in the 
context of their disease-oriented programmes. 
Physical mapping 
Physical mapping is, again, performed very competently by several groups on an ad 
hoc basis; in terms of large-scale approaches, the Alu fingerprinting procedure implemented 
by Daniel Cohen at Généthon (using the local automated blotting facilities and extensive 
computer facilities) contributes very significantly to the total mapping of the genome. This 
rapid and, for many, unexpected advance will induce major reassessment of physical mapping 
programmes elsewhere; it also raises the question of the distribution of the YACs which 
constitute the map: this is absolutely necessary but will require substantial resources as well 
as excellent organization. 
Sequencing 
There is substantial French participation to several collaborative sequencing 
programmes targeted on model organisms, notably yeast, Bacillus subtilis and Arabidopsis 
thaliana, and several cDNA sequencing projects are underway: at Généthon (Charles Auffiay), 
but also in several other laboratories. 
Informatics 
This field is one of the foci of the programme from the Ministry of Research. French 
groups have been quite active in this field, with the "ACNUC" DNA sequence database set 
up in Lyon, one of the first to handle such objects, the "GENATLAS" system developed for 
the HGM 9 meeting in Paris by Jean Frezal's group (a general genome database which is now 
to some extent a competitor of GDB) as well as "BISANCE", a general molecular biology 
utility system set up by Philippe Dessen and accessed by numerous users. However most of 
these endeavors have failed to reach the necessary critical size, and, in spite of the recognized 
strength of software development in France, their practical impact on genome research has so 
far remained too modest, although this may change with the growing popularity of ACeDB 
(see below). 
Π D 4. General comments (organizational) 
Many comments have already been made in the introductory section. It is to be hoped 
that effective implementation of the Ministry of Research genome programme will ease the 
present tensions and unify somewhat a community which at this time experiences serious 
tensions; meanwhile the important role of CEPH, the success of the "Généthon experiment" 
and the massive support of AFM to genome research should all be acknowledged and taken 
into account. 
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Π D 5. Recent developments 
Efforts are underway to organize all the Généthon data into a database format and to 
make it a generally available to the community. The format chosen is that of the very popular 
Nematode database, ACeDB, already used for the Arabidopsis project world-wide and for the 
Heidelberg Integrated Genome Database front end. Both the CEPH-Généthon physical maps 
and the cDNA project have attracted some criticism (Anderson, 1993 b): the reliability of the 
YACs (as faithful representations of genomic DNA) and of the maps is questioned, while it 
is claimed that many of the cDNAs sequenced in the Généthon project do not correspond to 
human sequences. Only time, and further experiments, will tell how serious these problems 
are. 
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Π Ε REST OF CONTINENTAL EUROPE 
Π E 1 . Ornent plans and major participants 
Excluding Great Britain and France, Europe accounts for a little more than 10% of the 
world output in human and general genetics, i.e. approximately twice as much as Japan for 
both fields. Its contribution is therefore far from negligible, but fairly dispersed and often 
difficult to differentiate from medical genetics. The four main producers of data are Germany, 
Italy, the Netherlands and the Nordic nations (Sweden, Norway, Finland and Denmark). 
Germany, by far the wealthier of these countries, has a relatively moderate 
involvement, with a programme for "Analysis of the human genome by molecular biological 
methods" funded at a yearly level of approximately 4 million Ecus, in addition to substantial 
investment in biomformatics. Human gene mapping is also included in various molecular 
biology projects, as well as the development of genome technology through informatics and 
instrumentation groups. Italy has had a human genome programme since 1987, centred on 
physical and genetic studies of the distal half of the long arm of the X chromosome, with an 
extensive network of œUabcrating laboratories. The Netherlands have a strong tradition of 
clinical genetics and molecular biology, and a newly started national genome programme; 
finally the Nordic countries have launched a coordinating "Nordic initiative", and a national 
programme is active in Sweden since mid­1992 (25 million crowns, i.e. 2.8 million ECUs, 
over three years). 
Π E 2. Assessment of progress 
Branching out from clinical genetics to genome work 
A number of excellent laboratories were originally medical genetics groups and have 
moved towards genomic studies. Some obvious and successful examples are the department 
of Medical Genetics in Leyden (previously led by Peter Pearson, now by Gert­Jan Van 
Ommen) that has become a major centre for sophisticated appUcations of non­isotopic in situ 
hybridization as well as of YAC technology, or Magnus Nordenskjöld's department in Uppsala 
Many other examples could be given. More rarely, some institutes have moved into the 
Genome field from general molecular biology, as is the case for the International Institute of 
Genetics and Biophysics in Naples with Michele DTJrso. The Italian case is rather unique as 
it is the only national project to focus explicitly on a particular chromosome region; this 
appears to have worked rather well, in particular thanks to close ties between several Italian 
groups and the Saint­Louis laboratory in the USA that established the first YAC library for 
this region. 
European instrumentation 
The existence of several centres developing original instrumentation or methods 
relevant to genome work is noteworthy. The most important is probably the instrumentation 
group of Wilhelm Ansorge at EMBL which has produced the only serious competitor to date 
for the ABI DNA sequencer (whose marketing was unfortunately delayed by almost two years 
because of the takeover of LKB by Pharmacia, otherwise it might have captured a much 
bigger market share). This group has developed additional instruments, such as a very high­
throughput DNA synthesizer and several robotic systems, which could have a significant 
impact. Other teams develop elegant methods (the OLA system in Uppsala, for example) 
which have great potential if they are taken up by competent industrial groups. 
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Π E 3. General commente (scientific) 
Contributions to the advancement of the human genome programme are very diverse 
and often stem from work done in the context of a particular genetic disease. 
Genome informatics is a potential strong point in Europe, but again the integration 
between biologists and software experts still leaves to be desired A central Bioinformatics 
Institute like that recently proposed by EMBL might be of great help if it was set up in a way 
ensuring good connection with, and input from, practising biologists. 
Π E 4. General comments (oigamzational) 
Few heavyweight structured centres 
In contrast to Great Britain and France, there are few large centres focussed on human 
genetics at a genomic level in me rest of Europe. 
USA vs the EEC 
The effect of the EEC genome programme in federating these groups is beginning to 
be felt, but - as is the general case for Biology in Europe - connections are often better with 
the USA than with other European countries. This is slowly changing, but, for example, the 
preferred country for a post-doc remains the USA 
Π E 5. Recent developments 
One of the most important recent development in Europe is the successful completion 
of the first yeast chromosome sequencing project, which has resulted in the complete sequence 
of chromosome ΙΠ. This landmark in DNA sequencing is scientifically important because of 
the wealth of new genes revealed and the réévaluations thus brought about. However its 
psychological impact is even more important: it shows that consortia of numerous European 
laboratories can be effective (although expensive) in spite of their cultural and technical 
differences, and, together with the striking recent successes of Généthon, it has strongly 
bolstered the morale of European groups and given them confidence that the USA is not the 
only environment in which large scientific projects can be successfully carried out The 
successes of Généthon groups in the fields of genetic and physical mapping are also very 
important factors in the emergence of Europe as a major "genomic power". 
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Π F. Former Soviet Union 
H F I . Ornent plans and major participante 
1989: A grand USSR Human Genome Programme 
At the initiative of several Russian scientists, in particular Alexander Bayev who liaised 
with Gorbatchev on this matter, a Human Genome programme was announced and launched 
in 1989. It was well funded: approximately 25 million roubles per year (at a time where one 
rouble was supposedly equivalent to one US dollar), with a specific allocation of 5 million 
roubles in foreign exchange. This represented quite a significant amount, to be compared, for 
example, with a total yearly budget of a few million roubles for a large research institute. The 
programme included all the usual categories of topics, with emphasis on specific chromosomes 
(3, 5, 13, 19). It also covered functional studies and medical genetics as well as instrument 
and reagent development. Several hundred grants were provided to scientists in a score of 
institutes, the average grant being relatively small (10 to 20,000 roubles). The visibility of the 
programme at the international level was high, with Andrei Mirzabekov (director of the 
Institute of Molecular Biology, Moscow) becoming vice-president of HUGO and the planned 
opening of a first HUGO office in Moscow. 
Genome research in the present Russian environment 
The programme is now essentially a Russian one. It is in fact considered as the most 
active biological research project in this country, and has received in 1992 a total of 130 
million roubles (^ The project is run from an office located at the Moscow Institute of 
Molecular Biology, and the funds are dispensed through this Institute. The whole programme 
is administered in a rather autonomous way by a scientific council and seven committees, one 
for each of the specific fields designated: 
- cell culture collection, chromosome isolation 
- clone libraries, physical mapping of chromosomes 
- human genome sequencing 
- structural-functional analysis 
- medical genetic mapping, gene therapy 
- software 
- instruments, reagents and probes 
As mentioned previously, individual grants are rather small: the whole budget is 
divided into ca. 750 units (rather quaintly called "genes"), a typical grant being one or two 
"genes"; some bigger projects may be funded at the level of five or ten "genes", but there has 
been no attempt to set up large specialised genome centers as in the US or elsewhere. 
Lit is extremely difficult to estimate how much this represents in actual purchasing power. 
If the sum is translated into US dollars using the going rate early 1993 (500 roubles to one 
dollar), the amount is almost ridiculous: less than 300,000 $. If however one uses as a 
yardstick the price of a Russian-made mid-range PCR machine (50, COO roubles), whose 
equivalent in the West is worm maybe 4,000 dollars, this budget comes out as more than 
10 million $... 
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Thus the main aim of the project appears to be stimulating and coordinating research related 
to genome studies in existing groups. 
Π F 2. Assessment of progress 
Off to a flying start 
Laboratory visits indicate that the Russian (or originally soviet) genome programme 
has had a significant impact It is clear that the major laboratories (mostly belonging to the 
Academy of Sciences) went on a buying spree in 1989/1990, and the level of equipment is 
very good DNA sequencers, Biomek robots, PC computers abound Genome funding 
represents a high percentage of lab income is some cases, and a large number of research 
projects have been started two or three years ago - especially so since the scope of the project 
was quite wide and could cover a good fraction of molecular biology. 
Difficulties linked to the collapse of the USSR 
Times have changed however, and the demise of the USSR has created many problems: 
loss of buying power because of the very high inflation, lack of foreign exchange, severance 
of ties with former Soviet republics that were significant scientific partners (such as Ukraine) 
or provided reagents payable in roubles (such as Lithuania for restriction enzymes). A number 
of scientists have left for Western laboratories, in principle for limited periods, but in fact 
permanently for a good proportion of them. In this context, the birth of a new program has 
been difficult, and the results so far relatively modest - although there are centers of 
excellence and groups operating at a very good level. 
Π F 3. General comments (scientific) 
A strong DOE flavour 
Discussions with Russian scientists involved in Genome research make it clear that the 
predominant conceptual influence comes from DOE groups and leaders such as Charles 
Cantor, Anthony Carrano or Bob Moyas. This may be accidental, but it could possibly reflect 
some similarities between DOE organization and soviet structures - at least when compared 
with the more free-wheeling MH style! Contacts with Europe (including Great-Britain) appear 
less developed, and there seems to be Utile collaboration with CEPH or Généthon groups. 
Approaches to specific chromosomes 
There does not seem to be extensive genetic mapping efforts in the country, apart from 
local mapping in the context of a given disease. This type of research is furthermore hampered 
by restricted access to patient populations now belonging to different, sometimes antagonistic 
countries. There is however a concerted physical mapping project centred on four 
chromosomes (3, 5,13,19). Part of this effort is invested in chromosome jumping and linking 
clone schemes rather similar to those advocated by Charles Cantor and Cassandra Smith, a 
couple of years ago. A set of apparently very efficient vectors has been developed to construct 
the corresponding jumping and linking libraries; the work is pursued, in particular on 
chromosome 3, in collaboration with George Klein's group in Sweden and involves the 
Moscow Molecular Biology Institute (Lev Kisselev). Interest on chromosome 13 is largely 
centred on the Wilson disease locus (13ql4-q21). Studies on chromosome 19 involve groups 
at the Moscow Molecular Biology Institute (Alexander Zelenin), at the Shemiakin Bioorganic 
Chemistry Institute and at tiie Institute of Molecular Genetics (both in Moscow) with Eugene 
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Sverdlov. The latter studies are to a large extent centred on expressed sequences, using several 
methods to specifically recover cDNA clones corresponding to genes present on this 
chromosome. SvedloVs group has initiated collaborations with Anthony Carrano's Genome 
center at Lawrence Livermore (USA). These various efforts appear to be of medium to high 
quality, but they are probably somewhat obsolescent now with recent progress on the whole-
genome physical map. 
DNA sequencing 
DNA sequencing is relatively well developed; Applied Biosystems or Pharmacia 
machines are installed and used in several laboratories; STS sequencing is done as well as 
sequencing of lhe jumping and linking clones mentioned above to find their overlaps. A large 
sequencing center (using conventional radioactive methods) is apparently active in Novosibirsk 
(Siberia), and performs contract sequencing for various institutions. In addition, Andrei 
MirzabekoVs group is one of the pioneers of sequencing by hybridization. They have 
developed a variation of the method solving one of its major problems (the differential 
stability of different sequences) and have made progress in the mMaturization of the 
"sequencing chips", in collaboration with a former military research laboratory. 
Π F 4. General conmente (oigarizational) 
Foreign exchange and brain drain 
Genome research suffers, as does the rest of Russian science, from the recent scarcity 
of foreign exchange. The present exchange rate (which does not reflect the actual cost of 
living within the country) makes any foreign reagent prohibitively expensive; thus well-
equipped and - until recently - well-staffed laboratories have been considerably slowed down. 
In addition academic salaries have not kept up with inflation. A senior scientist is paid (at the 
going rate) ten or twenty dollars per month. The actual buying power is at least ten times 
higher - still very insufficient, leading these professionals to spend part of their time in 
unrelated occupations. These two factors have promoted a significant brain drain, leaving some 
laboratories heavily understaffed. A few, such as the Moscow Molecular Biology Institute, 
have succeeded so far in limiting the problem by encouraging applications for Russian and 
foreign grants (which now make up 70% of the Institute's income), giving young scientist 
group leadership and allowing trebling of salaries from grant funds. Even there, however, the 
situation remains very fragile. Yet there still is a lot of potential in these groups, which could 
be released by funds provided in almost catalytic amounts. 
Self-reliance and 'reinventing the wheel" 
The relative isolation of Russian scientists in the past has forced them to be very self-
sufficient. To a certain extent this characteristic remains helpful in the present situation: lack 
of foreign exchange is partially compensated by local construction or modification of 
instruments, and several groups, for example, synthesize their own reagents for oligonucleotide 
assembly. This tendency can however be overdone and lead to efforts amounting to 
reinventing the wheel, discernible in the development of PC software packages for handling 
sequence data or for some vector developments. Contact with Western science is still restricted 
(for monetary rather than political reasons now), access to "grey" literature and grapevine 
information very limited, with the result that somewhat outdated or unpromising avenues of 
research are sometimes pursued too long. 
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Π F 5. Recent developments 
A very fluid situation 
The whole country is in a situation of flux, with very high inflation (20% per week) 
and looming political uncertainties. Understandably, science is not a first priority under these 
conditions, but the risk is that lasting damage can occur if this situation continues (or 
worsens), if more scientists leave the country while the presently abundant and still runctional 
equipment breaks down or becomes obsolete. Genome research, although privileged compared 
to other types of biological science, is also in danger. Yet the whole environment is probably 
too chaotic and unstable to envision large-scale, long-term projects. 
Need for modest but quick input 
As mentioned previously, some institutes are still very fimctional, with good equipment 
and qualified scientists. They only require very modest amounts of cash to, on one hand, 
purchase some vital supplies unobtainable within Russia, and on the other hand, provide salary 
supplements allowing researchers to stay in Russia and to do research full-time. The sums 
involved are very modest: hoped-for salary supplements are in the range of a hundred US 
dollars a month, and reagent requirements for a large Institute have been estimated at a total 
of 20,000 dollars per year. As an interim measure, a number of grants of this size for studies 
involving some collaboration with European groups, quickly awarded, could make a significant 
contribution to the survival of Russian science while providing useful genome data 
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ΠΙ. MAJOR ISSUES 
After this review of national programmes and progress, I will give an outlook (again, 
a highly personal one) on the present state in the four major components of genome 
programmes (genetic mapping, physical mapping, sequencing and informatics), and indicate 
how I see the evolution of these topics. 
ffl A. GESEnC MAPPING 
Initial successes and great expectations followed by difficulties 
The concept of a general genetic map of the human genome based on DNA 
polymorphisms is only a little over ten years old, but the construction of such a map has made 
tremendous progress since its first proposal by Botstein. Optimism was high in the mid to late 
eighties, with the publication in 1987 of the first general genetic map having an average 
spacing of 10 to 20 c^timorgans. Prediction o% and planning for, a 2 centimorgan map by 
1991 or 92 was incorporated, for example, in the US genome programme. Progress turned to 
be more difficult than anticipated, both because of the sheer amount of work required (with 
constant technology, a 2 centimorgan map requires a hundred times as much effort as a 20 
centimorgan map since ten times as many indviduals need to be studied with ten times as 
many probes), because of the rather uninspiring nature of the day to day effort involved and 
of a certain lack of interest by funding agencies. It was also felt, in some circles, that large-
scale physical maps based on pulsed field gel experiments and using "linking clones" were 
around the corner, and that they would make much of genetic mapping obsolete. 
Progress is resumed thanks to new technology 
However it was soon realized that physical maps would have to be based on contigs 
of cloned DNA segments to be really useful - and that this was not going to be easy. It also 
became apparent that in any case a complete and detailed genetic map with high quality 
landmarks was, and would remain, essential to the positional cloning ("reverse genetics") 
approaches. More polymorphic markers were found, first minisatellites or VNTRs, later CA 
repeats or microsatellites - so that by the time Southern blotting was more or less automated 
(e.g. at Généthon) RFLPs were no longer the main genetic mapping tool. Generation of large 
numbers of CA repeats is going ahead in a number of laboratories, and the first whole-
chromosome, and even whole genome, genetic maps based solely on CA repeats have already 
been published (Kazan et al, 1992; Weissenbach et al, 1992). Data capture and analysis using 
this system remain too cumbersome, and ways are being found to efficiently multiplex the 
assay of CA polymorphism and to call the results more or less automatically. Throughout this 
stage, as well as the preceding one, the general availabUity of the CEPH panel of families as 
DNA samples has played an important and very positive role - even though the required 
commitment of recipients to test the whole panel if a polymorphism was found was sometimes 
felt to be quite stringent. 
Two general maps have been published late in 1992, the one produced by collaborating 
groups using the CEPH panel (NIH/CEPH collaborative mapping group, 1992) and a "pure" 
rrricrosatellite map obtained by Jean Weissenbach's laboratory at Généthon (Weissenbach et 
al, 1992). Although less detailed (814 markers instead of 1416), the Généthon map is both 
more reliable (being constructed by a single group rather than assembled from many different 
sets of data) and more useful since it only incorporates highly polymorphic markers. 
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The importance of software 
The software available to perform generic analysis has made good progress (aided of 
course by the very large increase in computing power per dollar) and is now able to tackle 
difficult problems such as the search for genetic component in multifactorial diseases such as 
diabetes or hypertension, as well as in characteristics such as adult height or longevity. Input 
of data, however, remains a largely manual and error prone procedure which should be 
automated if at all possible or at least made much more user-friendly. 
The near future 
It now appears quite feasible to generate a density of markers (most of them highly 
polymorphic) equivalent to one per œntimorgan. This does not mean it will be easy to order 
all of them with respect to each other, since at such small recombination fractions the search 
for individuals with reœrnbinations in the interval becomes the dominant factor. It may 
however not be necessary to do this by genetic means, since efficient cytogenetic methods 
(interphase mapping, or even in situ hybridization to highly decondensed chromosomes) may 
be able to do this much more quickly. A recent variant of "sperm mapping", in which the 
whole DNA of a single sperm is first amplified with random primers (Zhang et al, 1992), thus 
making it possible in later stages to assay many markers on the same haploid DNA 
complement, may also become very significant. TTius the outlook for a high-resolution genetic 
map appears quite bright. 
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m R PHYSICAL MAPPING 
Substantial vs unsubstantial maps 
At the beginning of genome programmes the concept of whole chromosome physical 
maps based on pulsed field gel analysis of Not I cut genomic DNA complemented by a 
complete set of the corresponding linking clones (segments of DNA containing the rare Not 
I sites and a few kilobases of DNA on either side) was entertained by several groups. It soon 
became clear that this approach suffered from serious technical difficulties and shortcomings, 
and that a really reliable and useful map of a whole human chromosome had to based on a 
complete (or almost complete) set of overlapping cloned DNA segments - as done by Kohara 
et al for the E. coli genome in 1987. 
Are cosmids completely superseded by YACs? 
Contig building across human chromosomes was initiated, in particular for 
chromosomes 16 and 19 at Los Alamos and Lawrence livermore. This rather heroic 
undertaking (it takes 5,000 to 10,000 cosmids to cover such a piece of DNA) was pursued 
until coverage reached 60 to 70%, and benefited from the arrival of YACs which promise to 
make closure possible, as has been the case for the nematode genome. The extensive 
investment in cosmids was not a dead loss since, in practice, it turns out to be very useful to 
have a "cosmid layer" underlying a YAC contig map: cosmids provide DNA in a form which 
is very amenable to further experiments such as looking for genes. 
Chromosome-specific YAC libraries 
Qiromosome-specific YAC libraries are in principle an important resource for the 
construction of a physical map: alignment of the few hundred large YACs needed to cover an 
average-sized chromosome should be almost trivial compared to the equivalent endeavour with 
ten thousand cosmids. They can be obtained the hard way, by making a library from a suitable 
human-hamster hybrid cell line and subsequently screening for the few per cent of human-
specific clones, as done in Saint-Louis for the Xq24 to Xq28 library. Attempts to make such 
libraries from sorted chromosomes have given some promising results but have so far failed 
to provide complete libraries. The alternative route of "extracting" chromosome-specific 
components from a whole-genome YAC library is much more appealing, and recently two 
groups have reported success in doing this using as a mixed probe sequences derived from a 
chromosome-specific cosmid library (Ross et al, 1992) or from a somatic hybrid (Chumakov 
et al, 1992 a). 
What is the best way to obtain YAC contigs? 
It is now generally accepted that the primary whole-chromosome physical maps will 
be based on YACs, in spite of the problems with chimeric clones (Green et al, 1991 b), at 
least until some better vector comes along. Ab initio physical mapping of chromosomes 7 and 
X has been pursued in Saint-Louis, using "STS content mapping" (Green et al, 1991 a) and 
the whole genome YAC library. This approach relies on defining about one thousand STS per 
chromosome and then assaying YACs with the corresponding oligonucleotides. Positive YACs 
usually contain two or three such STS and can be overlapped with their neighbours by looking 
for the common STS. This very robust approach is work-intensive but reliable. Daniel Cohen's 
group at Généthon have used a somewhat similar STS content method to construct the 
complete chromosome 21 map (Chumakov et al, 1992 a), and a more adventurous 
fingerprinting technique to build contigs simultaneously over the whole genome. This project, 
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which uses the high-capacity blotting machines installed at Généthon, appears well on the way 
to produce a nearly continuous contig map of the whole genome (Bellanne-Chantelot et al, 
1992). 
The near future: complete - and available? - YAC contigs 
Thus complete (or almost complete) YAC-based physical maps of many whole 
chromosomes will soon be obtained These maps can be tremendously useful to the whole 
community, particularly so if they, and the underlying reagents, are made available in a 
convenient format In this respect, the example set by the nematode Community is worth 
considering. The LMB laboratory provides so-called "polytene filters" which contain a 
complete set of YACs ordered as they occur along the six Nematode chromosomes. The user 
simply hybridizes his probe to this filter and obtains two or three positive signals on adjacent 
spots, whose position on the filter immediately provide chromosome assignment and 
localization to within a hundred kilobases; the corresponding YACs and cosmids can then be 
obtained from the centre. This is one of the schemes which could be used to make available 
maps and reagents for each of the human chromosomes. 
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ΠΙ G SEQUENCING 
No breakthrough in methods (so far) 
When Genome programmes were first discussed in the mid-eighties, it was generally 
expected that sequencing technology would progress rapidly and that megabase sequencing 
at prices well below one dollar per base was just around the corner. Such progress has not 
occurred; instead several megabase sequencing projects initiated in the late eighties and aiming 
confidently at obtaining one or several megabases of sequence have failed to deliver the 
expected results: viz. the E. coli and Salmonella sequence, the human MHC region, or the 
Xq28 band The traditional sequencing method has been automated in part or (in Japan) in 
toto, but throughput in the latter case cannot yet be assessed; multiplex sequencing, a very 
rational approach, has run into serious difficulties with automating capture of the huge 
amounts of data produced Exotic methods such as STM and AFM have generated much initial 
excitement but have not yet demonstrated feasibility, the same is true for very fast techniques 
based on single molecule degradation and extremely sensitive analysis of single bases. 
Sequencing by hybridization is closer to a real-life feasibility demonstration; it certainly holds 
a lot of promise for detection of mutations in known genes and may well develop into the 
megasequencing method of the late nineties (Cantor et al, 1992; Pevzner et al, 1991). Efforts 
must be continued, since only radically new technologies are capable of bringing speed up, 
and cost down, by the one or two orders of magnitude necessary to make human genome 
sequencing a realistic task. 
The potential of well organized 'classical"'sequencing operations 
Current results show that it is feasible with present technology to sequence a few 
hundred kilobases, up to at least one megabase, at a cost of the order of one dollar per base. 
In this respect the model for near-future megabase sequencing appears to be the Nematode 
operation (Sulston et al, 1992) - rather than the EEC yeast effort (Oliver et al, 1992) which 
has been useful and worthwhile but very expensive (total cost 2.6 MEcus for 315 kilobases, 
i.e. close to ten dollars per base): sequencing will in the future have to be divided in larger 
chunks between a smaller number of centres. Sequencing at this cost is certainly worthwhile 
for model organisms with small genomes such as E. coli, Bacillus subtilis or even yeast; as 
genomes get larger (e.g. the 100 megabase Nematode genome) and less densely populated with 
genes, the answer becomes less obvious. In the human system megabase sequencing can only 
at this point be considered as a model experiment: sequencing a few one or two megabase 
long, particularly "interesting" regions, to find out how such sequencing actually goes in a 
genome very rich in repetitive sequences, how efficient present algorithms are at finding genes 
in such DNA... and whether anything unexpected comes out of such massive experiments. It 
will then be easier to decide whether, and how, to proceed 
cDNA sequencing 
Massive and partial cDNA sequencing was proposed several years ago, in particular 
by Sydney Brenner, but the most publicized implementation of this strategy occurred in the 
USA with Craig Venter at NDHL Ine approach has turned out to be quite effective at finding 
"new" genes, and provides partial sequence data on several thousands of hitherto unknown 
genes. It is practiced in a number of laboratories outside the USA, including the HGMP 
resource centre in Harrow, the Genethon (Charles Auffiay), the Osaka Institute of Molecular 
and Cellular Biology (Kenichi Matsubara) and others. Some scientific questions remain open: 
how effective is the approach at finding all, or even a significant fraction, of the existing 
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genes? For example, one may wonder how many of the 182 chromosome ΙΠ genes in yeast 
would have escaped detection by this approach. Another issue is the localization of the "new" 
genes revealed by this approach: even simple chromosome assignment is, at this time, very 
cumbersome (Polymeropoulos et al, 1952), and new methods (a high throughput non 
radioactive in situ hybridization technique routinely applicable to 0.5 kilobase segments, or 
preferably wide distribution of human YAC "polytene filters") are badly needed As these 
exercises continue, the question of real time data availability becomes more and more 
important, to avoid duplication of effort This has two aspects: data must be comparable, i.e. 
laboratories should agree to sequence the same region of cDNAs (5' or 3'), and it should be 
deposited and made accessible very quickly. Finally, of course, the vexing problem generated 
by attempts to patent these partial sequences should be resolved, ideally by a general decision 
not to indulge into such silly exercises. The recent negative ruling by the US patent office is 
naturally a big step in the right direction. 
Genomic DNA versus cDNA sequencing 
Discussion on the relative merits of these two approaches are heavily dependent on the 
organism considered and on the cost of large­scale sequencing. Under present conditions (one 
to two dollars per base) sequencing genomic DNA definitely makes sense for small genomes, 
up to a few megabases: a 5 megabase (E coli) or even 15 megabase (yeast) sequence is clearly 
feasible, and the wealth ofinformation provided (as shown by the recent nematode and yeast 
results) offsets the relatively high price of the exercise. The high gene density found in these 
organisms (one gene per two kilobases on average in yeast) reduces the saving which could 
be achieved by going the cDNA way. 
For larger genomes with mtron­containing genes (such as the 100 megabase nematode 
genome) the question becomes more debatable. For the human genome, if one takes the 
presently accepted upper limit for the number of genes of 100,000, and allows 1.5 Kilobases 
of coding sequence per gene, one ends up with an exon content of 5% ­ a figure which does 
make cDNA approaches attractive. So fer large human DNA sequences (the HPRT locus, and 
the T cell receptor region (Wilson et al, 1992)) do not appear to contradict current estimates 
of gene density ­ but the sample is too small to be representative. Indeed, if the Nematode 
uses 15,000 genes (the present estimate) for its relatively simple lifestyle and the coordination 
of its 959 cells, it may well be expected that a human being needs more than ten times that 
number: gene number and gene density would thus go up, and so would the attractiveness of 
genomic sequencing. In any case, if cost can be brought down to below 0.1 dollars a base by 
new techniques or by very efficiënt implementation of present methods, a whole chromosome 
could be sequenced for a sum of the order of 10 million dollars, i.e. roughly the amount 
previously budgeted for the physical map of such an entity in the US genome programme: 
large­scale sequencing would become irresistible. 
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ΠΙ D. INFORMATICS 
Informatics has been recognized from the start as a very important component of 
genome programmes, and has been funded accordingly, in particular in the USA Significant 
progress has been made, but the situation is still får from satisfactory because of the 
exponential growth in the amount of data and the bewildering variety of tasks which need to 
be addressed 
HI D 1. General genome databases 
Content and timeliness: the issue of unverified data 
Several genome databases have been established to cater to the growing needs of 
genome mappers. In addition to the familiar DNA sequence databases (EMBL and Genbank), 
there are systems storing all kinds of human mapping data (GDB), information on the mouse 
genome (GBASE), clinical description with mapping results (OMEM, GENATLAS) to name 
but a few. In principle these systems only store "public" data, either already published or 
adequately verified by expert inspection and released for general distribution. Thus the data 
is in most cases quite reliable, but often lags behind recent work; for example databases 
contain only a fraction of the microsatellite primers which have been defined over the world 
(Pearson et al, 1991). It would probably be very useful to display provisional data (flagged 
as such), since such non­verified results often provide very useful hints to others. 
Structure and user (un-) friendliness 
Databases have been developed over the years using a variety of database structures 
: IRX for OMM, SYBASE for GDB and GENATLAS, INGRESS for GBASE... Each of these 
systems has its own query structure and its particular quirks ; their only standard feature is 
their lack of user friendliness, which makes it relatively difficult for the average biologist to 
use them. A rising star in this world of databases is the Nematode system, ACeDB ("A 
Cenorhabditis elegans Data Base) which is winning over scientists from other fields thanks 
to its performance and ease of use: the system is now used for the Arabidopsis programme 
(AAtDB), by a some Drosophila groups, and it constitutes the front end of the Integrated 
Genome Database (IGD) being developed at the DKFZ in Heidelbgerg. 
Connection problems 
Because of their complex nature, of the variety of data stored and of the many ways 
in which links can be established between different kinds ofinformation, these databases are 
normally used on­line (the only exception being the sequence banks in their present ­ and 
transient ­ simple flat­file format). Accessing them implies not only a local computer (which 
is easy), but also a high­speed link to the database itself or to one of its secondary nodes, and 
sufficient local network expertise to actually establish the connection in a reliable way. While 
the high­speed link situation is relatively satisfactory in most of the USA, it is definitely not 
so in the rest of the world, yet using a database such as GDB with transmission speeds below 
9600 baud is essentially hopeless; local experts able to puzzle out an efficient connection are 
also very scarce. 
The growing power and dropping price of microcomputers and Unix workstations, in 
conjunction with these transmission problems, is causing a shift towards system in which a 
local (periodically refreshed) version of the database is used 
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ΠΙ D 2. Laboratoiy notebooks and local databases 
Computerized laboratory notebook systems are often discussed, but few groups actually 
implement and use mem. Yet the need is obvious: even partial automation leads to a large 
increase in the number of objects handled in the laboratory, thus rigourous and efficient data 
organization and storage become absolutely essential to avoid disaster. But the development 
of such a system for the average group is not easy, as it makes great demands on flexibility 
(objects, techniques and nature of data change quite often) and user friendliness (every 
scientist, student and technician should use the system daily), not to mention raw computing 
power and storage space (as images often have to be included in the data). Only fairly large 
groups organized around a common task seem to succeed in this endeavour, for example the 
Lawrence Livermore group which has set up a sophisticated and relatively easy to use system 
to record and follow progress on its cosmid fingeiprinting and contig building work (Stallings 
et aL 1992), or the Généthon team for their whole-genome contig building task (Bellanne-
Chantelot et aL 1992). Such large groups end up building local databases which must then be 
able to communicate with the "general" databases: this is best taken into account from the 
start, as it involves difficult informatics problems in addition to delicate questions of data 
ownership and restricted or general availability of the information. 
ΙΠ D 3. Software for comparing and interpreting sequences 
Comparing a sequence to all known sequences is a task whose complexity increases 
exponentially with the number of known sequences. Γη spite of the very rapid growth of 
computing power per dollar over the past decade, it is not certain that computers will keep up 
with the increasing flow of data. New algorithms are being perfected, and massively parallel 
machines, using dedicated hardware chips, may be the answer. Finding exons in a large 
genomic DNA sequence is still a vexing problem, as shown by the difficulties encountered in 
mterpreting a recent 106 Kilobase genomic sequence from chromosome 19 (Martín-Gallardo 
et aL 1992): the algorithm used found less than half of the exons subsequently detected by 
other methods. More work is clearly needed here. 
ΙΠ D 4. Communication problems 
Cbmmunication between biologists and computer scientists remains imperfect: they still 
belong, by and large, to two quite different cultures. Both fields have been evolving very 
quickly in recent years, and few individuals have real dual competence. An increase in their 
numbers, through attractive fellowships and positions, is probably the only way of easing this 
difficulty. 
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ΙΠ Ε INSmUMENTAIION 
A necessity... 
Newcomers to recombinant DNA laboratories, and even to genome centres, are often 
appalled by the predominance of manual work. Most procedures are performed by hand, 
machines being used only for a few specific steps. Even DNA "sequencers" only automate a 
small - albeit vital - part of the sequencing procedure. It appears obvious that to increase 
throughput and reproducibility the hands of the student, the technician or me post-doc must 
be replaced by machines - a feat which should not be impossible in this age of sophisticated 
electromechanical devices driven by cheap and powerful microprocessors. 
... Yet automated labs are few and far between 
In fact, even in specialized genome centres, manual work still predominates. Few 
laboratories, for example, have completely automated cosmid preparations; construction of 
YAC libraries still involves lengthy and tedious hand picking of clones into microtiter plates; 
and apart from a few pipeting robots (in most cases the Beckman Biomek machine, originally 
developed for Elisa assays) there are very few robots around Exceptions exist, the foremost 
being the "Genethon" centre set up near Paris by AFM and CEPH; another case - however not 
yet functional - is the HUGA "sequencing factory" in Tsukuba. But on the whole the 
penetration of instrumentation and robotics has been disappointingly slow in laboratories 
implementing human genome programmes (of course, it is even slower elsewhere). 
Understandable difficulties 
This unfortunate state of affairs reflects some very real problems. Recombinant DNA 
technology is still in a state of flux; thus a manufacturer's decision to develop an instrument 
automating a certain procedure entails a very serious risk: the probability is high that by the 
time the instrument is ready to be marketed (several years later) the procedure will have 
become obsolete. The "Labimap" Southern blotting machine has just been marketed, more than 
four years after the programme started, and by now PCR has replaced Southern blotting in 
most of its applications; likewise the HUGA set-up is based in part on obsolescent sequencing 
technology. In addition genome research, even today, is a relatively small sector: the market 
for a hypothetical high-throughput sequencing machine capable of reading 500,000 bases per 
working day is likely to be quite small - unless the resulting sequence is very affordable, a 
cent or less per base. Other, more "cultural" reasons hinder progress: most biologists are not 
very instrument-literate, and the race to a publishable result does not lend itself to careful 
investment in new technology, and communication between robotics specialists and biologists 
suffers some problems - as with informatics. 
Riture directions 
There are however some signs of progress. ABI has sold more than 800 sequencers 
world-wide, even though they are not all in actual use; semi-automated procedures based on 
the 96-well microtiter plate (or multiples thereof) are becoming more common; and instrument 
literacy, as well as computer knowledge, is increasing among biologists. Genome programmes 
have had a positive effect, by providing both the incentive and the funds for at least partial 
automation; and the demonstrated success of some groups in performing some routines by 
machine is now tempting smaller, more conventional laboratories to do the same. Concurrent 
increases in computing power per dollar for small computers make it easier to automate 
complex procedures: mechanical precision (always very expensive) can be substituted by 
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software sophistication - an increasingly available commodity. Numerous opportunities exist 
in this field, both for research groups to operate more effectively and for astute companies to 
generate cash flow and profits. 
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IV. CONCLUSIONS AND PEBSPECIWES 
It is difficult to draw conclusions in such a study at a time when events are moving 
so rapidly. Clearly the balance has shifted in recent months towards Europe, with the success 
of enterprises such as yeast whole-chromosome sequencing, whole genome physical maps and 
refined genetic maps. Agencies in the US have, as usual, been quick to assess the new 
situation and to launch new centers incorporating some of the features of Généthon (Roberts, 
1992; Anderson, 1993) and in attracting the CEPH Mega Yac library to the other side of the 
Atlantic. 
Even though I have deliberately avoided discussing the EEC programme as such 
(noting only the areas in which its effects have been felt), it is clear that it has a great role to 
play in capitalizing on this - possibly temporary - success to establish a more balanced 
relationship with the USA Making the results of whole genome physical mapping readily 
available to the community will be an extensive but necessary task; it must be tackled by 
informatie means (an accessible, complete and user-fìiendly datábase), but also at the level of 
the distribution of YAC clones, a very labour-intensive task. Making these reagents readily 
accessible to all European scientists (e.g.. by wide distribution of "polytene filters" containing 
ordered YACs for all human chromosome) would be an essential step in this direction. 
In view of very widespread criticism directed to GDB, it becomes useful to envision 
alternative databases or at least different database access systems: in this respect, the progress 
on the Heidelberg ICD appears quite promising and the distributed model advocated on this 
group, using a locally running ACeDB system fed with data from the other genome databases, 
appears particularly promising. 
Finally attention, and some funding, should be devoted to improving interfaces between 
the "genome world" and the general biology community, including not only medical genetics 
but also, for example, groups performing functional research in the mouse system so that 
structure and function are brought closer together. 
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